Keybanc analyst Michael Turits downgrades Rapid7 (NASDAQ:RPD) from Overweight to Sector Weight.
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs For Patients Using GIMOTI Over Oral Metoclopramide Presented At The American College Of Gastroenterology 2023
Evoke Pharma, Inc. (NASDAQ:EVOK),a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, and
